Alterations of G1-S checkpoint in chordoma: The prognostic impact of p53 overexpression

Cancer

Volumn 104, Issue 6, 2005, Pages 1255-1263

  Naka, Takahiko ^a,c   Boltze, Carsten ^a   Kuester, Doerthe ^a   Schulz, Torss Oliver ^a   Schneider Stock, Regine ^a   Kellner, Angela ^a   Samii, Amir ^b   Herold, Christian ^b   Ostertag, Helmut ^b   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

^c KYUSHU ROSAI HOSPITAL   (Japan)

Author keywords

Chordoma; Cyclin D1; Murine double minute 2; p53; Pleomorphism; Prognosis; Retinoblastoma protein

Indexed keywords

CYCLIN D1; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; BONE TUMOR; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHORDOMA; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; ADOLESCENT; CHEMISTRY; CHILD; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; CHORDOMA; CYCLIN D1; G1 PHASE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; S PHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 24644446358     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21296     Document Type: Article

References (38)

1. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
2. Greenblatt M, Benett W, Hollstein M, Harris C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
3. Sherr C. Cancer cell cycles. Science. 1996;274:1672-1677.
4. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol. 1994;145:287-293.
5. Ewen M, Sluss H, Sherr C, Matsushime H, Kato J, Livingston D. Functional interaction of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993;73:487-497.
6. Grana X, Reddy E. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211-219.
7. Naka T, Boltze C, Samii S, et al. Skull base and non-skull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003;98:1934-1941.
8. Cote R, Dunn M, Chatterjee S, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998;58: 1090-1094.
9. Stefanaki K, Tzardi M, Kouvidou C, et al. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res. 1998;18:2403-2408.
10. Kohn GJ, Schwartz HJ, Buebner BH, Wong AJ, Lawson MJ. Colonic retinoblastoma protein and proliferation in cancer and non-cancer patients. J Gastroenterol Hepatol. 1997;12: 198-203.
11. Ioachim E, Assimakopoulos D, Agnantis N, Peschos D, Zissi A, Skevas A. Altered patterns of retinoblastoma gene product expression in benign, premalignant and malignant epithelium of the larynx: an immunohistochemical study including correlation with p53, bcl-2 and proliferating indices. Anticancer Res. 1999;19:541-546.
12. Schneider-Stock R, Haeckel C, Radig K, Pein C, Roessner A. Improved detection of p53 mutations in soft tissue tumors using new gel composition for automated non radioactive analysis of single-strand conformation polymorphism. Electrophoresis. 1997;18:2849-2851.
13. Goldmann D, Merril C. Silver staining of DNA in polyacrylamide gels: linearity and effect of fragment size. Electrophoresis. 1982;3:24-26.
14. Bergh P, Kindblom L, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom J. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-2134.
15. Pallini R, Maira G, Pierconti F, et al. Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg. 2003;98: 812-822.
16. Chehab N, Malikzay A, Appel M, Halazonetis T. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev. 2000;14:278-288.
17. Shieh S, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000;14:289-300.
18. Shieh S, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334.
19. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999;18:22-27.
20. ARF stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 1999;96:6937-7941.
21. Zhang Y, Xiong Y, Yarbrough W. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4A locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-734.
22. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA. 1999;96:14973-14977.
23. Cordon-Cardo C, Lastres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54:794-799.
24. Lianes P, Orlow I, Zhang Z, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994;86:1325-1330.
25. Capoulade C, Bressac-de Paillerets B, Lefrere I, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 1998;16:1603-1610.
26. ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002;21:3525-3531.
27. Shvarts A, Steegenga W, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15:5349-5357.
28. Riemenschneider M, Buschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999;59:6091-6096.
29. Landers J, Haines D, Strauss JI, George D. Enhanced translation: a novel mechanism of mdm2 oncoprotein overexpression identified in human tumor cells. Oncogene. 1994;9:2745-2750.
30. Olson D, Marechal V, Momand J, Chen J, Romocki C, Levine A. Identification and characterization of multiple mdm2 proteins and mdm2 p53 protein complexes. Oncogene. 1993; 8:2353-2360.
31. Wurl P, Meye A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 1998;16:1183-1185.
32. Patterson H, Gill S, Fisher C, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer. 1994;69:1052-1058.
33. Jones S, Hancock A, Vogel H, Donehower L, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA. 1998;22:15608-15612.
34. Sigalas I, Calvert A, Anderson J, Neal D, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med. 1996;2:912-917.
35. Cordon-Cardo C, Zhang Z, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997;57:1217-1221.
36. Oshiro Y, Chaturvedi V, Hayden D, et al. Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study. Cancer. 1998;83:2324-2334.
37. de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer. 2000;89: 783-792.
38. Taubert H, Meye A, Wurl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 1996;56:4134-4136.